Table 1:
Sample description of the ACTG175 study variables considered by the PRIM algorithm. The arms are labeled as 0 = zidovudine, 1 = zidovudine and didanosine, 2 = zidovudine and zalcitabine, 3 = didanosine.
| Treatment Group | |||||
|---|---|---|---|---|---|
| Variable | 0 (n = 532) | 1 (n = 522) | 2 (n = 524) | 3 (n = 561) | P-value |
|
| |||||
| Age | 0.984 | ||||
| ≤ 30 | 166 (0.31) | 164 (0.31) | 164 (0.31) | 177 (0.32) | |
| (30,40] | 237 (0.45) | 233 (0.45) | 235 (0.45) | 251 (0.45) | |
| (40,50] | 102 (0.19) | 101 (0.19) | 95 (0.18) | 111 (0.20) | |
| > 50 | 27 (0.05) | 24 (0.05) | 30 (0.06) | 22 (0.04) | |
|
| |||||
| Weight (kg) | 0.749 | ||||
| ≤ 60 | 44 (0.08) | 63 (0.12) | 58 (0.11) | 66 (0.12) | |
| (60,70] | 138 (0.26) | 126 (0.24) | 132 (0.25) | 132 (0.24) | |
| (70,80] | 177 (0.33) | 175 (0.34) | 172 (0.33) | 192 (0.34) | |
| > 80 | 173 (0.33) | 158 (0.30) | 162 (0.31) | 171 (0.30) | |
|
| |||||
| Hemophilia | 0.946 | ||||
| No | 490 (0.92) | 479 (0.92) | 478 (0.91) | 512 (0.91) | |
| Yes | 42 (0.08) | 43 (0.08) | 46 (0.09) | 49 (0.09) | |
|
| |||||
| Homosexual activity | 0.679 | ||||
| No | 191 (0.36) | 176 (0.34) | 176 (0.34) | 182 (0.32) | |
| Yes | 341 (0.64) | 346 (0.66) | 348 (0.66) | 379 (0.68) | |
|
| |||||
| Karnofsky score | 0.500 | ||||
| 70 | 4 (0.01) | 0 (0.00) | 3 (0.01) | 2 (0.00) | |
| 80 | 17 (0.03) | 22 (0.04) | 18 (0.03) | 23 (0.04) | |
| 90 | 197 (0.37) | 189 (0.36) | 180 (0.34) | 221 (0.39) | |
| 100 | 314 (0.59) | 311 (0.60) | 323 (0.62) | 315 (0.56) | |
|
| |||||
| Prior antiretroviral therapy | 0.350 | ||||
| No | 516 (0.97) | 513 (0.98) | 511 (0.98) | 552 (0.98) | |
| Yes | 16 (0.03) | 9 (0.02) | 13 (0.02) | 9 (0.02) | |
|
| |||||
| Race | 0.452 | ||||
| White | 376 (0.71) | 384 (0.74) | 374 (0.71) | 388 (0.69) | |
| Non-white | 156 (0.29) | 138 (0.26) | 150 (0.29) | 173 (0.31) | |
|
| |||||
| Gender | 0.708 | ||||
| Female | 100 (0.19) | 88 (0.17) | 89 (0.17) | 91 (0.16) | |
| Male | 432 (0.81) | 434 (0.83) | 435 (0.83) | 470 (0.84) | |
|
| |||||
| 0.528 | |||||
| Baseline CD4 count | 75 (0.14) | 98 (0.19) | 88 (0.17) | 86 (0.15) | |
| ≤ 15.3 | 182 (0.34) | 175 (0.34) | 175 (0.33) | 197 (0.35) | |
| (15.3,18.4] | 197 (0.37) | 171 (0.33) | 173 (0.33) | 201 (0.36) | |
| (18.4,21.6] | 78 (0.15) | 78 (0.15) | 88 (0.17) | 77 (0.14) | |
| > 21.6 | |||||
|
| |||||
| Baseline CD8 count | 0.813 | ||||
| ≤ 6.32 | 72 (0.14) | 79 (0.15) | 69 (0.13) | 88 (0.16) | |
| (6.32,6.79] | 197 (0.37) | 173 (0.33) | 181 (0.35) | 192 (0.34) | |
| (6.79,7.26] | 190 (0.36) | 183 (0.35) | 195 (0.37) | 203 (0.36) | |
| > 7.26 | 73 (0.14) | 87 (0.17) | 79 (0.15) | 78 (0.14) | |